Example: Heart Attack

Clinical Trials on Wet Macular Degeneration

Total 324 results

NCT04049266

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Conditions: Wet Macular Degeneration
NCT01448538

Completed

Non-Persistence/Non-Adherence (NP/NA) in Wet Age-related Macular Degeneration (wAMD) Patients in Germany

Conditions: Wet Macular Degeneration
NCT01617148

Completed

Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept

Conditions: Exudative Macular Degeneration
NCT02060604

Completed

Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration

Conditions: Wet Macular Degeneration
NCT02541084

Completed

Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan

Conditions: Wet Macular Degeneration
NCT04420923

Recruiting

Optimizing the Treatment Strategy for Age-related Macular Degeneration

Conditions: Wet Macular Degeneration
NCT02289924

Completed

Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy

Conditions: Wet Macular Degeneration
NCT03823287

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

Conditions: Wet Macular Degeneration
NCT03823300

Enrolling by invitation

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

Conditions: Wet Macular Degeneration
NCT03861234

Recruiting

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

Conditions: Wet Macular Degeneration
NCT02121522

Completed

A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration

Conditions: Wet Macular Degeneration
NCT02944227

Completed

Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration

Conditions: Wet Macular Degeneration
NCT02279537

Completed

Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD

Conditions: Wet Macular Degeneration
NCT02305238

Completed

Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration

Conditions: Wet Macular Degeneration
NCT04698850

Not yet recruiting

Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation

Conditions: Wet Macular Degeneration
NCT03022292

Active, not recruiting

The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy

Conditions: Wet Macular Degeneration
NCT01896284

Completed

Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor

Conditions: Wet Macular Degeneration
NCT02321241

Completed

Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD

Conditions: Wet Macular Degeneration
NCT01243086

Completed

OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab

Conditions: Wet Macular Degeneration
NCT01249937

Unknown status

Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab

Conditions: Wet Macular Degeneration
NCT03278262

Completed

The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting

Conditions: Wet Macular Degeneration
NCT02540369

Completed

To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.

Conditions: Wet Macular Degeneration
NCT02806752

Unknown status

Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy

Conditions: Wet Macular Degeneration
NCT03034772

Completed

Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration

Conditions: Neovascular Age-related Macular Degeneration; Wet Macular Degeneration
NCT02689518

Completed

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

Conditions: Macular Degeneration; Wet Macular Degeneration